The global Alopecia Treatment Market was valued at USD 3.4 Billion in 2024 and is projected to grow to USD 4.8 Billion by 2033, registering a CAGR of 3.9% during the forecast period 2025-2033. Growth is propelled by rising alopecia prevalence, increased healthcare spending, and heightened aesthetic awareness worldwide, with North America holding the largest market share of over 38.34% in 2024.

STUDY ASSUMPTION YEARS

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

ALOPECIA TREATMENT MARKET KEY TAKEAWAYS

• Current Market Size: USD 3.4 Billion in 2024
• CAGR: 3.9%
• Forecast Period: 2025-2033
• North America dominates with over 38.34% market share in 2024.
• Increasing prevalence of alopecia due to aging, hormonal imbalances, and autoimmune disorders is boosting demand.
• Rising healthcare expenditure worldwide supports greater access to advanced treatments.
• Growing aesthetic consciousness driven by social media and beauty standards is expanding market demand.
• Expansion of e-commerce platforms is improving treatment accessibility, especially in developing regions.

Sample Request Link: 

https://www.imarcgroup.com/alopecia-treatment-market/requestsample

MARKET GROWTH FACTORS

The alopecia treatment market growth is significantly driven by the increasing prevalence of alopecia globally. For instance, androgenetic alopecia affects a considerable share of the population, including 15% of postmenopausal women and over 50% of elderly males, with thinning hair appearing from puberty. Alopecia areata affects about 700,000 persons in the U.S and 2% of the global population. This rising incidence, combined with heightened awareness and advances in medical technologies such as regenerative medicine and stem cell therapy, has boosted demand for effective treatment options.

Escalating healthcare expenditure worldwide also underpins market growth. Global healthcare spending rose by 21% on average in 2020, climbing to 25% higher than 2019 levels in 2021. Developed countries exhibited notable per capita health spending growth,for example, Belgium increased by 9.6% between 2021-2022, and the US by 2.9%. This growing financial capability and disposable income enable broader access to emerging alopecia therapies, fueling market expansion.

The market is further propelled by growing aesthetic consciousness globally, with increased focus on appearance influenced by social media and cultural beauty ideals. According to the International Society of Hair Restoration Surgery, members treated an average of 165 surgical and 396 non-surgical patients in 2021. The demand for hair restoration reflects individuals’ self-consciousness and desire to meet aesthetic standards, thereby accelerating investments in innovative treatments and supporting the alopecia treatment market’s growth.

MARKET SEGMENTATION

Drug Type:

• Minoxidil: A popular, FDA-approved topical treatment that stimulates hair growth and is affordable compared to prescriptions. It is widely adopted for male and female pattern hair loss.
• Finasteride
• Others

Indication:

• Androgenic Alopecia: Leading segment with around 37.6% share in 2024, driven by high global prevalence and awareness.
• Alopecia Areata
• Alopecia Totalis
• Others

Gender:

• Male
• Female: Leading with 59.8% market share in 2024, owing to rising prevalence and female-focused treatment options like minoxidil.

Route of Administration:

• Oral
• Topical: Holds the largest share, favored for ease of use and fewer systemic effects.
• Injectable

Distribution Channel:

• Hospitals: Leading segment with 40.3% share in 2024, attributed to specialized medical expertise and infrastructure.
• Retail Pharmacies
• Online Pharmacies

REGIONAL INSIGHTS

North America dominates with a market share of over 38.34% in 2024. The region benefits from a robust healthcare infrastructure, high alopecia prevalence, and significant awareness of treatment options. The U.S. leads within North America, accounting for 93.40% of the regional market share in 2024, driven by demand for advanced pharmaceutical therapies such as JAK inhibitors and strong investment in research and development.

RECENT DEVELOPMENTS & NEWS

• July 2024: FDA approved Sun Pharma’s Leqselvi (deuruxolitinib) 8 mg tablets for severe alopecia areata in adults following successful Phase III trials.
• July 2024: Aclaris Therapeutics sold future OLUMIANT (baricitinib) royalties and milestones related to alopecia areata to OMERS for up to USD 31.5 Million.
• February 2024: NICE recommended Pfizer’s Ritlecitinib (Litfulo) as the first treatment for severe alopecia areata on the NHS for patients aged 12 and above.
• February 2024: Pelage Pharmaceuticals raised USD 16.75 million Series A funding for Phase 2 trials of a topical treatment for androgenetic alopecia.
• December 2023: Aclaris Therapeutics granted Sun Pharma exclusive rights under a USD 15 Million patent license for deuruxolitinib to treat alopecia areata and androgenetic alopecia.

KEY PLAYERS

• Aclaris Therapeutics Inc.
• Cellmid Limited
• Cipla Limited
• Dr. Reddy’s Laboratories Ltd.
• GlaxoSmithKline plc
• HCell Inc.
• Johnson & Johnson
• Merck & Co. Inc.
• Pfizer Inc.
• Taisho Pharmaceutical Holdings Co. Ltd
• Teva Pharmaceutical Industries Ltd.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

ABOUT US

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

CONTACT US

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302